Patients with a diagnosis of metastatic or locally advanced unresectable melanoma
Patients treated with first-line immunotherapy as monotherapy (e.g., pembrolizumab or nivolumab) or in combination (e.g., ipilimumab - nivolumab or nivolumab - relatlimab)
Patients treated at IEO (Milan) from 01/01/2022 to 30/11/2027
Age ≥18 years
You may not be if
Patients who received targeted therapy as first-line treatment for metastatic melanoma
Patients with a diagnosis of resectable stage III melanoma or operated stage IV with no evidence of disease (NED)
Clareo Health | Markers of Efficacy to Immunotherapy in Patients With Metastatic Melanoma
